129 related articles for article (PubMed ID: 26835904)
1. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
Mandelia C; Collyer E; Mansoor S; Lopez R; Lappe S; Nobili V; Alkhouri N
J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):181-7. PubMed ID: 26835904
[TBL] [Abstract][Full Text] [Related]
2. Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease.
Wang A; Blackford AL; Behling C; Wilson LA; Newton KP; Xanthakos SA; Fishbein MH; Vos MB; Mouzaki M; Molleston JP; Jain AK; Hertel P; Harlow Adams K; Schwimmer JB;
Hepatology; 2024 Jun; 79(6):1381-1392. PubMed ID: 37870272
[TBL] [Abstract][Full Text] [Related]
3. Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative.
Pitisuttithum P; Chan WK; Goh GB; Fan JG; Song MJ; Charatcharoenwitthaya P; Duseja A; Dan YY; Imajo K; Nakajima A; Ho KY; Goh KL; Wong VW; Treeprasertsuk S
World J Gastroenterol; 2020 May; 26(19):2416-2426. PubMed ID: 32476802
[TBL] [Abstract][Full Text] [Related]
4. A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease.
Liang J; Liu F; Wang F; Han T; Jing L; Ma Z; Gao Y
Biomed Res Int; 2017; 2017():8793278. PubMed ID: 28349067
[No Abstract] [Full Text] [Related]
5. Development and Validation of the Nonalcoholic Fatty Liver Disease Familial Risk Score to Detect Advanced Fibrosis: A Prospective, Multicenter Study.
Huang DQ; Ahlholm N; Luukkonen PK; Porthan K; Amangurbanova M; Madamba E; Bettencourt R; Siddiqi H; Cervantes V; Hernandez C; Lopez SJ; Richards L; Nemes K; Isoniemi H; Yki-Järvinen H; Loomba R
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):81-90.e4. PubMed ID: 37406954
[TBL] [Abstract][Full Text] [Related]
6. Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis.
Yang M; Xu D; Liu Y; Guo X; Li W; Guo C; Zhang H; Gao Y; Mao Y; Zhao J
PLoS One; 2015; 10(6):e0131664. PubMed ID: 26121037
[TBL] [Abstract][Full Text] [Related]
7. Elevated Serum Level of Cytokeratin 18 M65ED Is an Independent Indicator of Cardiometabolic Disorders.
Qian L; Zhang L; Wu L; Zhang J; Fang Q; Hou X; Gao Q; Li H; Jia W
J Diabetes Res; 2020; 2020():5198359. PubMed ID: 32337295
[TBL] [Abstract][Full Text] [Related]
8. Elevation of plasma tRNA fragments as a promising biomarker for liver fibrosis in nonalcoholic fatty liver disease.
Huang P; Tu B; Liao HJ; Huang FZ; Li ZZ; Zhu KY; Dai F; Liu HZ; Zhang TY; Sun CZ
Sci Rep; 2021 Mar; 11(1):5886. PubMed ID: 33723340
[TBL] [Abstract][Full Text] [Related]
9. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods.
Yoneda M; Imajo K; Takahashi H; Ogawa Y; Eguchi Y; Sumida Y; Yoneda M; Kawanaka M; Saito S; Tokushige K; Nakajima A
J Gastroenterol; 2018 Feb; 53(2):181-196. PubMed ID: 29177681
[TBL] [Abstract][Full Text] [Related]
10. Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis.
Kar S; Paglialunga S; Jaycox SH; Islam R; Paredes AH
PLoS One; 2019; 14(7):e0217263. PubMed ID: 31291245
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study.
Morling JR; Fallowfield JA; Williamson RM; Nee LD; Jackson AP; Glancy S; Reynolds RM; Hayes PC; Guha IN; Strachan MW; Price JF
Liver Int; 2014 Sep; 34(8):1267-77. PubMed ID: 24237940
[TBL] [Abstract][Full Text] [Related]
12. Secondary bile acids improve risk prediction for non-invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease.
Liu AN; Xu CF; Liu YR; Sun DQ; Jiang L; Tang LJ; Zhu PW; Chen SD; Liu WY; Wang XD; Targher G; Byrne CD; Wong VW; Fu J; Su MM; Loomba R; Zheng MH; Ni Y
Aliment Pharmacol Ther; 2023 Apr; 57(8):872-885. PubMed ID: 36670060
[TBL] [Abstract][Full Text] [Related]
13. Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
Cummings J; Ranson M; Lacasse E; Ganganagari JR; St-Jean M; Jayson G; Durkin J; Dive C
Br J Cancer; 2006 Jul; 95(1):42-8. PubMed ID: 16804528
[TBL] [Abstract][Full Text] [Related]
14. Preliminary study on the diagnostic value of LEAP-2 and CK18 in biopsy-proven MAFLD.
Liu Z; Ren Q; Mu H; Zeng Y; An Z; He H
BMC Gastroenterol; 2024 May; 24(1):182. PubMed ID: 38778244
[TBL] [Abstract][Full Text] [Related]
15. Presence of Alpha 1 Antitrypsin Risk Variants is Not Associated With Histologic Severity of Pediatric NAFLD.
Khan M; Klepper C; Orkin S; Arce-Clachar AC; Bramlage K; Fei L; Miethke A; Kohli R; Xanthakos S; Mouzaki M
J Pediatr Gastroenterol Nutr; 2023 Aug; 77(2):166-170. PubMed ID: 37229749
[TBL] [Abstract][Full Text] [Related]
16. Fungal signature differentiates alcohol-associated liver disease from nonalcoholic fatty liver disease.
Viebahn G; Hartmann P; Lang S; Demir M; Zhang X; Fouts DE; Stärkel P; Schnabl B
Gut Microbes; 2024; 16(1):2307586. PubMed ID: 38298161
[TBL] [Abstract][Full Text] [Related]
17. Serum level of full-length connective tissue growth factor reflects liver fibrosis stage in patients with Fontan-associated liver disease.
Kogiso T; Takayanagi K; Ishizuka T; Otsuka M; Inai K; Ogasawara Y; Horiuchi K; Taniai M; Tokushige K
PLoS One; 2024; 19(1):e0296375. PubMed ID: 38166061
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic scores and scales for appraising Nonalcoholic fatty liver disease and omics perspectives for precision medicine.
Perez-Diaz-Del-Campo N; Martínez-Urbistondo D; Bugianesi E; Martínez JA
Curr Opin Clin Nutr Metab Care; 2022 Sep; 25(5):285-291. PubMed ID: 35788123
[TBL] [Abstract][Full Text] [Related]
19. Markers of adipose tissue fibrogenesis associate with clinically significant liver fibrosis and are unchanged by synbiotic treatment in patients with NAFLD.
Bilson J; Oquendo CJ; Read J; Scorletti E; Afolabi PR; Lord J; Bindels LB; Targher G; Mahajan S; Baralle D; Calder PC; Byrne CD; Sethi JK
Metabolism; 2024 Feb; 151():155759. PubMed ID: 38101770
[TBL] [Abstract][Full Text] [Related]
20. Letter to the editor: diagnosing fibrosis and cirrhosis in nonalcoholic fatty liver disease using machine learning models.
Feng Y; Peng B; Li Y; Sun L; Sun Y
Hepatology; 2023 May; 77(5):E103-E104. PubMed ID: 36645222
[No Abstract] [Full Text] [Related]
[Next] [New Search]
